Sanofi drops €610m on new vaccine research and manufacturing sites in France

pharmafile | June 16, 2020 | News story | Manufacturing and Production COVID-19, Sanofi 

The coronavirus outbreak has changed the way that the world prioritises healthcare resources, and lay bare just how unprepared many countries were in the event of a pandemic. Now, Sanofi has announced it will funnel €610 million into a new project to build a new vaccine manufacturing facility and research site in its home country of France.

The Evolutive Vaccine Facility (EVF), a vaccine production centre in Neuville sur Saône, will feature several digital production models housed within a central unit, allowing for the production of three or four vaccines at the same time, accelerating production speed by more than double current methods. Sanofi will invest €490 million into the project over five years. The project is expected to create 200 new jobs, with an overriding objective to guard against future pandemics

The company also confirmed it would be investing €120 million to construct a new digital research facility at the existing Sanofi Pasteur site at Marcy-l’Etoile. Featuring a number of specialised laboratories, the facility will monitor and research emerging diseases and pandemic risks with the goal of developing vaccines pre-emptively against these threats.

“Sanofi’s heart beats in France. We have a long history and exceptional teams working throughout the country, embodying our strong values. By investing in a new industrial site and a R&D centre, Sanofi positions France at the core of its strategy, aiming to make France a world-class centre of excellence in vaccine research and production,” said Paul Hudson, Chief Executive Officer at Sanofi. “Sanofi is a major healthcare player in France, in Europe, and worldwide. It is our responsibility to focus our resources and expertise against the current pandemic, but also to invest in preparing for future ones. We welcome the ongoing collaboration and commitment of the French authorities who we have been working alongside with the last several months to achieve this.”

Matt Fellows

Related Content

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …

Maze Therapeutics and Sanofi sign exclusive worldwide license agreement for Pompe disease treatment

Maze Therapeutics and Sanofi have announced that they have signed an exclusive worldwide license agreement …


Moderna and Pfizer COVID-19 vaccine protection declines over time

Data presented by Pfizer and Moderna ahead of the FDA’s vaccine advisory committee meeting on …

Latest content